Key Details
Annual Revenue
$1.16 MAnnual EPS
-$1.95Annual ROE
-90.02%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 10, 2024Recent annual earnings:
Mar 09, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 26, 2024Analyst ratings
Recent major analysts updates
28 July '23 Baird
Neutral15 May '23 HC Wainwright & Co.
Buy12 May '23 Credit Suisse
Neutral12 May '23 Chardan Capital
Buy16 Mar '23 HC Wainwright & Co.
Buy17 Nov '22 Chardan Capital
Buy11 Nov '22 RBC Capital
Sector Perform31 Aug '22 Baird
Outperform16 Aug '22 Credit Suisse
Neutral16 Aug '22 Chardan Capital
BuyScreeners with FIXX included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Homology Medicines doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
FIXX
Zacks Investment Research11 May 2023
Homology Medicines (FIXX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.20 per share a year ago.
FAQ
- What is the primary business of Homology Medicines?
- What is the ticker symbol for Homology Medicines?
- Does Homology Medicines pay dividends?
- What sector is Homology Medicines in?
- What industry is Homology Medicines in?
- What country is Homology Medicines based in?
- When did Homology Medicines go public?
- Is Homology Medicines in the S&P 500?
- Is Homology Medicines in the NASDAQ 100?
- Is Homology Medicines in the Dow Jones?
- When was Homology Medicines's last earnings report?
- When does Homology Medicines report earnings?
- Should I buy Homology Medicines stock now?
What is the primary business of Homology Medicines?
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
What is the ticker symbol for Homology Medicines?
The ticker symbol for Homology Medicines is NASDAQ:FIXX
Does Homology Medicines pay dividends?
No, Homology Medicines does not pay dividends
What sector is Homology Medicines in?
Homology Medicines is in the Healthcare sector
What industry is Homology Medicines in?
Homology Medicines is in the Biotechnology industry
What country is Homology Medicines based in?
Homology Medicines is headquartered in United States
When did Homology Medicines go public?
Homology Medicines's initial public offering (IPO) was on 28 March 2018
Is Homology Medicines in the S&P 500?
No, Homology Medicines is not included in the S&P 500 index
Is Homology Medicines in the NASDAQ 100?
No, Homology Medicines is not included in the NASDAQ 100 index
Is Homology Medicines in the Dow Jones?
No, Homology Medicines is not included in the Dow Jones index
When was Homology Medicines's last earnings report?
Homology Medicines's most recent earnings report was on 10 May 2024
When does Homology Medicines report earnings?
The date for Homology Medicines's next earnings report has not been announced yet
Should I buy Homology Medicines stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions